Regular ArticleLow-Dose N-Butyldeoxynojirimycin (OGT 918) for Type I Gaucher Disease☆
References (5)
- et al.
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis
Lancet
(2000) - et al.
Glucosylceramide lipidoses
There are more references available in the full text version of this article.
Cited by (0)
- ☆
Communicated by E. Beutler, M.D., 02/08/02
- f1
Correspondence and reprint requests to: Deborah Elstein, Gaucher Clinic, Shaare Zedek Medical Center, P.O. Box 3235, Jerusalem 91031, Israel. Fax: +972-2-651-7979. E-mail: [email protected].
Copyright © 2002 Elsevier Science (USA). All rights reserved.